Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoramidis in ATTR-CM
NCT07695701Phase 4Recruiting
- Sponsor
- BridgeBio Pharma
- Start
- Jul 2026
- Primary completion
- Aug 2030
- Countries
- 1
01
Overview
A Phase 4 trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by BridgeBio Pharma. Started Jul 2026; status: recruiting.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT07695701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07695701.